Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.50 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4664791 | 1.00 | KLK7 (0.52) | KLK7ABHD6DAGLAPARP1DPP4 | |
| SCHEMBL7908488 | 1.00 | KLK7 (0.52) | KLK7ABHD6DAGLAPARP1DPP4 | |
| SCHEMBL20129716 | 0.96 | DAGLA (0.54) | KLK7ABHD6DAGLAPARP1DPP4 | |
| SCHEMBL6610814 | 0.96 | DAGLA (0.54) | KLK7ABHD6DAGLAPARP1DPP4 | |
| SCHEMBL7921496 | 0.93 | KLK7 (0.47) | KLK7ABHD6DAGLAPARP1PRMT5 | |
| SCHEMBL7921498 | 0.93 | KLK7 (0.47) | KLK7ABHD6DAGLAPARP1PRMT5 | |
| SCHEMBL30428955 | 0.90 | DAGLA (0.48) | KLK7ABHD6DAGLAPARP1PRMT5 | |
| SCHEMBL12260685 | 0.88 | KLK7 (0.42) | KLK7ABHD6DAGLAPARP1PRMT5 | |
| SCHEMBL6610956 | 0.87 | KLK7 (0.50) | KLK7ABHD6DAGLAPARP1PRMT5 | |
| SCHEMBL8188560 | 0.87 | FKBP1A (0.52) | KLK7MEN1KMT2AOPRD1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200206189-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-07-02 | — | — | US | disclosed |
| US-20180179218-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. | 2018-06-28 | — | — | US | disclosed |
| CN-105229011-B | Spirolactams nmda receptor conditioning agent and application thereof | 阿普廷伊克斯股份有限公司 | 2018-02-06 | — | — | CN | disclosed |
| US-9828384-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170231956-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2017-08-17 | — | — | US | disclosed |
| US-9579304-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Aptinyx, Inc. (US) | 2017-02-28 | — | — | US | disclosed |
| CN-103582482-B | Pharmaceutically active disubstituted triazine derivatives | 利德探索中心有限公司 | 2016-10-12 | — | — | CN | disclosed |
| CN-103582482-A | Pharmaceutically active disubstituted triazine derivatives | LEAD DISCOVERY CENTER GMBH | 2014-02-12 | — | — | CN | disclosed |
| CN-1905868-A | DPP-IV inhibitors | GRAFFINITY PHARMACEUTICALS AG (CH) | 2007-01-31 | — | — | CN | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179218-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KLK7 2980/4885ABHD6 3516/4885DAGLA 3874/4885 |
| US-20170231956-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KLK7 2980/4885ABHD6 3516/4885DAGLA 3874/4885 |
| US-20200206189-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KLK7 2980/4885ABHD6 3516/4885DAGLA 3874/4885 |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | KLK7 2980/4885ABHD6 3516/4885DAGLA 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.